Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most claims match the provided GRALISE label excerpts (indication, substitutability, not substituting with IR, once-daily evening meal, titration table concept, and avoidance of substitution on a mg-for-mg basis). Minor issues include imprecision/unsupported specificity about the meaning of the “Gralise 300 mg” wording and an omission failure to cover multiple label safety points (e.g., contraindication hypersensitivity, specific gradual discontinuation timeframe, respiratory depression monitoring, and renal impairment restrictions).
Category Scores
Accurate Statements
Gralise is an extended-release (ER) formulation of gabapentin.
Consistent with GRALISE being gabapentin ER per the provided label excerpts (indication/treatment and PK/administration with evening meals; ER formulation not explicitly stated in the excerpts, so support is indirect).
“Gralise 300 mg” refers to the tablet strength of 300 mg each.
GRALISE dosage forms and strengths include tablets of 300 mg.
Gralise (gabapentin ER) is used to treat postherpetic neuralgia.
Indications and Usage: GRALISE is indicated for management of postherpetic neuralgia.
Postherpetic neuralgia is a chronic pain condition that can occur after shingles.
Not supported or contradicted by the provided excerpts (no descriptive definition included).
Gralise is generally taken as directed for once-daily dosing.
Dosage and Administration: titrate to 1,800 mg once daily with the evening meal.
Gralise should not be replaced with immediate-release gabapentin on a mg-for-mg basis.
Label states GRALISE is not substitutable with other gabapentin products and “Do not use GRALISE as a substitute for other gabapentin products.” (mg-for-mg basis not explicitly stated in excerpts, but the substitution prohibition supports the concept).
The specific titration schedule for Gralise depends on the prescriber’s instructions.
Label says GRALISE should be titrated as outlined (Table 1) and that gradual discontinuation timing is “at the discretion of the prescriber” (this claim is partially supported by the prescriber discretion concept, but the excerpt does not state titration schedule depends on prescriber instructions; it provides a recommended schedule).
Gralise 300 mg is not interchangeable with other gabapentin products.
Label: GRALISE is not substitutable with other gabapentin products.
Switching between Gralise and immediate-release gabapentin is not a direct strength conversion.
Supported by “not substitutable” / “Do not use as a substitute” statements; direct strength conversion language not explicitly present.
Unsupported Statements
“Gralise 300 mg” ... each used for dosing regimens that are typically taken once daily with food.
The excerpts confirm once-daily with the evening meal and that strengths exist, but they do not explicitly state that the specific 300 mg strength is “typically taken once daily with food” as a definitional meaning of the product name.
Postherpetic neuralgia is a chronic pain condition that can occur after shingles.
No such definition/characterization appears in the provided label excerpts.
The specific titration schedule for Gralise depends on the prescriber’s instructions.
The label provides a recommended titration schedule (Table 1) rather than stating the titration schedule depends on prescriber instructions.
Contradictions
Important Omissions
Contraindication: hypersensitivity to the drug or its ingredients.
Importance:
High
Titration details: specifically titrate to 1,800 mg once daily with the evening meal, and swallow whole (do not split/crush/chew).
Importance:
High
Discontinuation/substitution should be done gradually over a minimum of one week or longer (at prescriber discretion).
Importance:
High
Warnings: respiratory depression risk with CNS depressants (especially opioids) and need to monitor for symptoms of respiratory depression and sedation when co-prescribed or in underlying respiratory impairment.
Importance:
High
Warnings: increased risk of suicidal thoughts/behavior with AEDs including gabapentin; reports after discontinuation.
Importance:
Moderate
Warnings: DRESS/multiorgan hypersensitivity has been reported.
Importance:
Moderate
Renal impairment: must initiate at 300 mg; titrate per Table 1; GRALISE should not be administered in CrCl <30 or in patients receiving hemodialysis.
Importance:
High
Specific population limitations: safety/effectiveness not studied in pediatric patients (<18) for postherpetic neuralgia.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While several substitution-related claims align with the label, the response omits multiple high-importance safety and administration elements (contraindication, gradual discontinuation minimum timeframe, respiratory depression monitoring, and renal impairment restrictions), which could lead to incomplete safe-use communication.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing multiple key prescribing-information safety/administration details (contraindications, gradual discontinuation timing, respiratory depression monitoring, renal impairment exclusions/adjustments). Also contains a couple of unsupported/overly specific statements (postherpetic neuralgia definition; implication that titration schedule depends on prescriber instructions).
Suggested Improvement
Add/align key label elements: contraindication hypersensitivity; titrate to 1,800 mg once daily with evening meal and swallow whole; if reduced/discontinued/substituted, do so gradually for at least one week or longer; include respiratory depression monitoring with CNS depressants/opioids and in underlying respiratory impairment; include renal impairment initiation/titration rules and the “do not administer” exclusions (CrCl <30; hemodialysis); avoid stating that titration schedule depends on prescriber instructions when Table 1 is provided.